Viaskin Peanut Development Progress
Successful results from the Phase III efficacy study, EPITOPE, for toddlers aged 1 to 3 years met its primary endpoint. Enrollment for the VITESSE Phase III trial in children aged 4 to 7 years is expected to complete by the end of Q3 2024.
Cash Runway Extension
Due to cost-saving measures, DBV Technologies has extended its cash runway into Q1 of 2025, an extension from the previous estimate of year-end 2024.
Financial Efficiency
Operating income for the first semester of 2024 reached $2.6 million, with efforts to maximize efficiency and maintain disciplined cash management.